Lv41
500 积分 2022-11-06 加入
Toxicities following CAR-T therapy for hematological malignancies
8小时前
待确认
How I treat post-immunotherapy relapsed B-ALL
8小时前
待确认
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
11小时前
已完结
Bispecific and multispecific antibodies in oncology: opportunities and challenges
11天前
已完结
The present and future of bispecific antibodies for cancer therapy
12天前
已完结
Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
4个月前
已完结
Safety and Efficacy of Blinatumomab in Japanese Adult and Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Final Results from an Expansion Cohort
4个月前
已完结
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results
4个月前
已完结
Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis
5个月前
已完结
Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis
5个月前
已关闭
皖公网安备34019202002308
